Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,380 result(s) found. Displaying page 2,113 of 2,219.
    «« First « Previous 2109  2110  2111  2112  2113  2114  2115  2116  2117  Next» Last»»
    EudraCT Number: 2020-003061-19 Sponsor Protocol Number: CL1-65487-003 Start Date*: 2021-01-07
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Phase I / II, open label, dose escalation part (phase I) followed by non-comparative expansion part (phase II), multi-centre study, evaluating safety, pharmacokinetics and efficacy of S65487, a Bcl...
    Medical condition: Previously untreated Acute Myeloid Leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) FR (Trial now transitioned) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002341-42 Sponsor Protocol Number: CCSJ117A12201E1 Start Date*: 2021-10-13
    Sponsor Name:Novartis Pharma AG
    Full Title: A 24-week, multicenter, randomized, double-blind, parallel-arm, placebo-controlled extension study to assess the safety of CSJ117, when added to existing standard of care asthma therapy in patients...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Prematurely Ended) PL (Prematurely Ended) SK (Prematurely Ended) IT (Prematurely Ended) LV (Prematurely Ended) DE (Completed) BE (Completed) BG (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002332-73 Sponsor Protocol Number: 2020/CHU/05 Start Date*: 2020-07-16
    Sponsor Name:Centre Hospitalier Universitaire de la Réunion
    Full Title: Promotion of sexual health and promotion of a papillomavirus vaccination program in middle school
    Medical condition: Gardasil 9 is indicated for the active immunization of individuals from 9 years old against diseases due to HPV
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002031-29 Sponsor Protocol Number: R7257-RAA-1947 Start Date*: 2020-11-05
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A PHASE 1/2 STUDY OF REGN7257 (ANTI-INTERLEUKIN 2 RECEPTOR SUBUNIT GAMMA [IL2RG] MONOCLONAL ANTIBODY) IN PATIENTS WITH SEVERE APLASTIC ANEMIA THAT IS REFRACTORY TO OR RELAPSED ON IMMUNOSUPPRESSIVE ...
    Medical condition: SEVERE APLASTIC ANEMIA
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10002274 Anemia aplastic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001488-10 Sponsor Protocol Number: APHP200080 Start Date*: 2020-10-05
    Sponsor Name:Assistance Publique Hopitaux de Paris
    Full Title: Multisite open-label randomized phase II clinical trial in newly diagnosed glioblastoma treated by concurrent TemoRadiation and adjuvant temozolomide +/- ultrasound-induced blood brain barrier opening
    Medical condition: Newly diagnosed Glioblastoma (IDH wild-type) patients at initial radiological diagnosis eligible for tumor resection , and for the standard of care including concurrent temoradiation and adjuvant T...
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000721-11 Sponsor Protocol Number: CHPAU2019/03 Start Date*: 2020-09-24
    Sponsor Name:Centre hospitalier de PAU
    Full Title: Management of Anticoagulant Therapy monitored by an implantable device with telecardiology in patients with Acute Coronary Syndrome associated with de novo atrial Fibrillation Arrhythmia (SCA-FA): ...
    Medical condition: acute coronary syndrome and atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000591-34 Sponsor Protocol Number: 123456 Start Date*: 2011-05-06
    Sponsor Name:Mater University Hospital
    Full Title: SIRS Steroids In caRdiac Surgery Trial
    Medical condition: Study Objective(s) To determine whether high-risk patients undergoing cardiac surgery requiring CPB derive benefit from perioperative steroids. Study Design Multicentre, International, random...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003114-12 Sponsor Protocol Number: HBIG Start Date*: 2022-11-04
    Sponsor Name:Medical University of Graz
    Full Title: Impact of Hepatitis B immunoglobulins in patients with chronic Hepatitis B on Hepatocellular Carcinoma – a proof of concept study
    Medical condition: Patients with both chronic hepatitis B and hepatocellular carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002041-36 Sponsor Protocol Number: POLARIS2009-001 Start Date*: 2011-11-15
    Sponsor Name:Polaris Group
    Full Title: A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Fai...
    Medical condition: Advanced Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10019829 Hepatocellular carcinoma recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-000075-33 Sponsor Protocol Number: OMS721-IGA-001 Start Date*: 2018-06-07
    Sponsor Name:Omeros Corporation
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS – IGAN)
    Medical condition: IgA nephropathy (IgAN)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) SK (Prematurely Ended) LT (Prematurely Ended) SE (Completed) ES (Prematurely Ended) BE (Completed) AT (Prematurely Ended) PL (Prematurely Ended) BG (Completed) GB (GB - no longer in EU/EEA) DE (Completed) IT (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003914-42 Sponsor Protocol Number: CEFTAROLINE_RRT Start Date*: 2013-11-06
    Sponsor Name:Medizinische Universität Wien, Univ.-Klinik für Innere Medizin I, Klinische Abteilung für Infetionen und Tropenmedizin
    Full Title: Multiple-dose Pharmacokinetics of Ceftaroline during continuous and intermittent renal replacement therapy in patients requiring renal replacement therapy
    Medical condition: Bacterial infection in patients recieving renal replacement therapy
    Disease: Version SOC Term Classification Code Term Level
    16.0 10021881 - Infections and infestations 10060945 Bacterial infection PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-006804-34 Sponsor Protocol Number: CYP003 Start Date*: 2022-09-27
    Sponsor Name:Cytovation ASA
    Full Title: A Phase 1b/2a, Open-Label, Multi-Center Study of CyPep-1 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety of CyPep-1 in Patients With Advanced or Metastatic Head and Neck Squam...
    Medical condition: Advanced or metastatic: -Head and Neck Squamous Cell Carcinoma (HNSCC); -Melanoma; -Triple-Negative Breast Cancer (TNBC);
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000673-24 Sponsor Protocol Number: PHRC_N_2018_BAY Start Date*: 2021-04-15
    Sponsor Name:CHU de Clermont-Ferrand
    Full Title: Faecal microbiota transplantation for prevention of graft-versus-host sisease after allogeneic stem cell transplantation for haematological malignancies
    Medical condition: Patient who underwent Allogeneic hematopoietic stem cell transplantation (allo-HSCT) for various haematological malignancies. Faecal microbiota transplantation (FMT) will be assessed to prevent al...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000471-20 Sponsor Protocol Number: RIPH_2019_01 Start Date*: 2020-11-30
    Sponsor Name:CH Tourcoing
    Full Title: Rifabutin versus rifampicin for treatment of staphylococcal prosthetic joint infection treated with debridement, antibiotics and implant retention (DAIR strategy): a multicenter randomized, open-la...
    Medical condition: Adult with an staphylococcal prosthetic joint infection treated with debridement, antibiotics and implant retention (DAIR strategy)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10065011 Prosthesis related infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000155-12 Sponsor Protocol Number: 2018_49 Start Date*: 2020-05-12
    Sponsor Name:InBrain Pharma SAS
    Full Title: A new concept of continuous dopaminergic stimulation by cerebroventricular administration of A-dopamine (dopamine stored in anaerobia) for severe motor fluctuations in Parkinson’s disease?
    Medical condition: Proof of concept study: prospective, monocentric, controlled randomized study according a cross over design with 2 groups: cerebroventricular administration of A-dopamine versus optimized oral trea...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000039-33 Sponsor Protocol Number: 2018-06-017 Start Date*: Information not available in EudraCT
    Sponsor Name:Groupement de Coopération Sanitaire Ramsay Générale de Santé pour l’Enseignement et la Recherche
    Full Title: Multicentric, double-blind, randomized study to show that the addition of IV tranexamic acid versus placebo in ACL ligamentoplasties leads to a decrease in blood loss and postoperative pain
    Medical condition: Patients undergoing primary ACL ligamentoplasty with hamstring tendon removal on an outpatient basis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-004793-26 Sponsor Protocol Number: HPN217-3001 Start Date*: 2020-06-24
    Sponsor Name:Harpoon Therapeutics, Inc.
    Full Title: A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients with Relapsed/Refractory Multiple Myeloma
    Medical condition: Relapsed/Refractory Multiple Myeloma (RRMM)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004554-29 Sponsor Protocol Number: KRT-232-109 Start Date*: 2020-07-24
    Sponsor Name:Kartos Therapeutics, Inc.
    Full Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or...
    Medical condition: Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post-ET-MF)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074689 Post polycythemia vera myelofibrosis LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074690 Post essential thrombocythemia myelofibrosis LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074691 Post polycythaemia vera myelofibrosis LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074692 Post essential thrombocythaemia myelofibrosis LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077161 Primary myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Completed) BG (Completed) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004195-19 Sponsor Protocol Number: CREPATS10 Start Date*: 2020-07-07
    Sponsor Name:Centre de Recherche et d’Etudes sur la Pathologie Tropicale et le Sida (CREPATS)
    Full Title: A randomized comparative phase II trial evaluating the capacity of the dual combination doravirine/raltegravir to maintain virological success in HIV-1 infected patients with an HIV-RNA plasma vire...
    Medical condition: HIV disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10020160 HIV disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003106-31 Sponsor Protocol Number: MK-3475-B15 Start Date*: 2021-04-27
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants wit...
    Medical condition: Urothelial Carcinoma and Muscle Invasive Bladder Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064467 Urothelial carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) PT (Trial now transitioned) GR (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned) HU (Trial now transitioned) HR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2109  2110  2111  2112  2113  2114  2115  2116  2117  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Feb 10 08:37:51 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA